Lilly Wins TRO Battle In Byetta Marketing Case

Law360, New York (June 8, 2011, 7:30 PM EDT) -- A California federal judge on Wednesday lifted an order blocking Eli Lilly & Co. from selling Amylin Pharmaceuticals Inc.'s diabetes drug Byetta alongside a rival company's drug, saying Amylin's fears about the marketing deal were unfounded.

U.S. District Judge Janis L. Sammartino said Amylin had no firm evidence that Lilly sales representatives who sold both Byetta and Boehringer Ingelheim GmbH's competing Tradjenta would lie about Byetta's effectiveness in order to boost Tradjenta's sales. Lilly sells both drugs, which treat Type 2 diabetes, under separate marketing agreements...
To view the full article, register now.